SD Biosensor Inc - Asset Resilience Ratio
SD Biosensor Inc (137310) has an Asset Resilience Ratio of 13.59% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check how strategically is SD Biosensor Inc's equity deployed to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2024)
This chart shows how SD Biosensor Inc's Asset Resilience Ratio has changed over time. See SD Biosensor Inc balance sheet quality to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down SD Biosensor Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see SD Biosensor Inc stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩541.28 Billion | 13.59% |
| Total Liquid Assets | ₩541.28 Billion | 13.59% |
Asset Resilience Insights
- Moderate Liquidity: SD Biosensor Inc has 13.59% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
SD Biosensor Inc Industry Peers by Asset Resilience Ratio
Compare SD Biosensor Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Gan & Lee Pharmaceuticals Co Ltd
SHG:603087 |
Medical Instruments & Supplies | 9.87% |
|
Andon Health Co Ltd
SHE:002432 |
Medical Instruments & Supplies | 18.11% |
|
Pegavision
TW:6491 |
Medical Instruments & Supplies | 17.14% |
|
Tarsons Products Limited
NSE:TARSONS |
Medical Instruments & Supplies | 0.47% |
|
SciVision Biotech Inc
TW:1786 |
Medical Instruments & Supplies | 7.81% |
|
Nyxoah
BR:NYXH |
Medical Instruments & Supplies | 12.40% |
|
I.Ceram SA
PA:ALICR |
Medical Instruments & Supplies | -1.61% |
|
Ansell Ltd
AU:ANN |
Medical Instruments & Supplies | 7.53% |
Annual Asset Resilience Ratio for SD Biosensor Inc (2019–2024)
The table below shows the annual Asset Resilience Ratio data for SD Biosensor Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 7.47% | ₩290.33 Billion ≈ $196.75 Million |
₩3.89 Trillion ≈ $2.64 Billion |
+5.48pp |
| 2023-12-31 | 1.99% | ₩75.33 Billion ≈ $51.05 Million |
₩3.79 Trillion ≈ $2.57 Billion |
-4.05pp |
| 2022-12-31 | 6.04% | ₩197.03 Billion ≈ $133.52 Million |
₩3.26 Trillion ≈ $2.21 Billion |
-27.70pp |
| 2021-12-31 | 33.74% | ₩1.01 Trillion ≈ $687.11 Million |
₩3.01 Trillion ≈ $2.04 Billion |
+18.61pp |
| 2020-12-31 | 15.13% | ₩221.15 Billion ≈ $149.87 Million |
₩1.46 Trillion ≈ $990.54 Million |
+3.30pp |
| 2019-12-31 | 11.83% | ₩20.08 Billion ≈ $13.60 Million |
₩169.72 Billion ≈ $115.02 Million |
-- |
About SD Biosensor Inc
SD Biosensor, Inc., together with its subsidiaries, operates as an in-vitro diagnostic company in South Korea, India, Asia, Europe, the Americas, and Africa. The company offers STANDARD Q, which provides rapid diagnostic products; STANDARD F, a fluorescence immunodiagnostic system for various qualitative and quantitative diagnosis items; STANDARD E, an enzyme immunoassay diagnosis for large-volum… Read more